Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD
Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD
复制标题
DOI：
10.1155/2019/8194804
复制
发表时间：
2019-01-01
影响因子：
--
通讯作者：
Guo, Shi-ning
中科院分区：
文献类型：
--
作者：
Lv, Wei-jie;Liu, Cui;Guo, Shi-ning
一般来说，炎症性肠病（IBD）可以由心理，基因，环境和肠道微生物群引起。因此，IBD的治疗应加以改进，以利用多种策略。参苓白术散坚持从整体、综合的角度治疗复杂疾病，是治疗炎症性肠病的有效方法。在本文中，系统药理学和微生物群方法被开发用于以SLBZS为例的这些分子机制。首先，通过系统吸收-分布-代谢-排泄（ADME）分析，检索潜在活性化合物及其相应的直接靶标。然后，建立活性化合物、靶点和疾病之间的网络关系，推断药物的药理作用。最后，提出了一个由多个调控模块组成的“IBD通路”，以剖析SLBZS的治疗作用。此外，通过分析V3-V4区域和多变量统计方法评估SLBZS对肠道微生物群的影响。SLBZS显著改变了大鼠模型中的肠道微生物群结构。综上所述，我们发现SLBZS对IBD相关生理过程的调节具有多维度性，这为中药治疗IBD提供了新的视角。
Generally, inflammatory bowel disease (IBD) can be caused by psychology, genes, environment, and gut microbiota. Therefore, IBD therapy should be improved to utilize multiple strategies. Shen Ling Bai Zhu San (SLBZS) adheres to the aim of combating complex diseases from an integrative and holistic perspective, which is effective for IBD therapy. Herein, a systems pharmacology and microbiota approach was developed for these molecular mechanisms exemplified by SLBZS. First, by systematic absorption-distribution-metabolism-excretion (ADME) analysis, potential active compounds and their corresponding direct targets were retrieved. Then, the network relationships among the active compounds, targets, and disease were built to deduce the pharmacological actions of the drug. Finally, an "IBD pathway" consisting of several regulatory modules was proposed to dissect the therapeutic effects of SLBZS. In addition, the effects of SLBZS on gut microbiota were evaluated through analysis of the V3-V4 region and multivariate statistical methods. SLBZS significantly shifted the gut microbiota structure in a rat model. Taken together, we found that SLBZS has multidimensionality in the regulation of IBD-related physiological processes, which provides new sights into herbal medicine for the treatment of IBD.